CEO & President Joshua Brumm Sells 100,000 Shares of Dyne Therapeutics Inc (DYN) [Yahoo! Finance]
Dyne Therapeutics, Inc. (DYN)
Last dyne therapeutics, inc. earnings: 11/1 04:30 pm
Check Earnings Report
US:NYSE Investor Relations:
dynegy.com/investors/presentations-events
Company Research
Source: Yahoo! Finance
recent SEC Filing . The transaction was executed at an average price of $28.96 per share, resulting in a total value of $2,896,000. Warning! GuruFocus has detected 3 Warning Signs with DYN. Dyne Therapeutics Inc ( NASDAQ:DYN ) is a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases. The company leverages its proprietary FORCE platform to enhance the delivery of therapeutics to muscle tissues. Over the past year, the insider, Joshua Brumm, has sold a total of 729,656 shares of Dyne Therapeutics Inc ( NASDAQ:DYN ) and has not made any purchases of the stock. This latest transaction continues a pattern of insider sales for the company. The insider transaction history for Dyne Therapeutics Inc ( NASDAQ:DYN ) indicates a trend of more insider sales than purchases over the past year. There has been a total of 1 insider buy and 50 insider sells during this period. On the date of the insider's recent sale, shares of Dyne
Show less
Read more
Impact Snapshot
Event Time:
DYN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DYN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DYN alerts
High impacting Dyne Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DYN
News
- SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive OfficerGlobeNewswire
- Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium [Yahoo! Finance]Yahoo! Finance
- Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy SymposiumGlobeNewswire
DYN
Earnings
- 3/5/24 - Miss
DYN
Sec Filings
- 4/5/24 - Form ARS
- 4/5/24 - Form DEFA14A
- 4/5/24 - Form DEF
- DYN's page on the SEC website